Though FGFR4 inhibitors are unlikely to deplete existing metastatic tumors as they are not cytotoxic, preventing or delaying further lesions could allow standard of care chemotherapies to prove more efficacious and extend survival. This evidence concerns the gene FGFR4 and metastatic neoplasm.